Ladenburg Thalmann Downgrades Noven Pharmaceuticals (NOVN) to Neutral
More News related to NOVN
- After-Hours Movers 8/18: SPRD, CLZR, IPAS, LZB, KTCC, SIGM Higher; VTG, ADPI, ADI, LFT, GA, HPQ Lower
- S&P Announces Update to US Indices Liquidity Criteria; SIGM to Replace NOVN
- Caris Downgrades Noven Pharma (NOVN) to Neutral
- Ladenburg Thalmann Downgrades Noven Pharmaceuticals (NOVN) to Neutral
- Unusual 11 Mid-Day Movers 7/14: HITK, NOVN, NSU, IMMU Higher; SBGI, CPF, HNT, COBZ Lower
More News related to Downgrades
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
Ladenburg Thalmann downgrades Noven Pharmaceuticals (Nasdaq: NOVN) from Buy to Neutral.
To see more analyst ratings on NOVN Click Here.
Noven Pharmaceuticals, Inc. engages in the research, development, manufacture, licensing, marketing, and sale of prescription pharmaceutical products.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
